Phase 2
Completed N=463
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
Source: ClinicalTrials.gov NCT01319812 ↗Enrolled (actual)
463
Serious AEs
53.3%
Results posted
Jun 2017
Primary outcomePrimary: Effectiveness Endpoint for the Pulsar Stent: Primary Patency — 66.8 Percentage of participants
Summary
The objective of this study is to separately demonstrate the safety and efficacy of BIOTRONIK's Astron and Pulsar stents. The Pulsar stent will be used for the treatment of femoro-popliteal lesions, located in the native superficial femoral artery (SFA) or proximal popliteal artery (PPA), while the Astron stent will be used for the treatment of the common or external iliac artery lesions.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Effectiveness Endpoint for the Pulsar Stent: Primary Patency |
66.8 | — |
| PRIMARY Safety Endpoint for the Pulsar Stent: Freedom From Procedure- or Stent-related Major Adverse Events |
99.7 | — |
| PRIMARY Safety and Effectiveness Endpoint for the Astron Stent - Percentage of Participants With Major Adverse Events (MAE) |
2.1 | — |
| PRIMARY Percentage of Participants With Primary Safety Endpoint (Post Market Analysis) |
78.2 | — |
| SECONDARY Secondary Safety Assessment for the Pulsar Stent: Individual Rates of Mortality, TLR, and Index Limb Amputation |
99.7; 100.0; 100.0 | — |
| SECONDARY Long-Term Safety Assessment for the Pulsar Stent: Major Adverse Event Rate |
0.4; 12.4; 0.4 | — |
| SECONDARY Stent Integrity Assessment for the Pulsar Stent: Stent Fracture Rate |
14; 4; 3; 3; 4; 0 | — |
| SECONDARY Secondary Safety Assessment for the Astron Stent - Distribution of MAE Rate |
0.7; 1.4; 0.0 | — |
| SECONDARY Secondary Effectiveness Assessment for the Astron Stent - Primary Patency Rate |
89.8 | — |
| SECONDARY Secondary Effectiveness Assessment for the Astron and Pulsar Stents - Primary Assisted Patency |
97.9; 98.9 | — |
| SECONDARY Secondary Effectiveness Assessment for the Astron and Pulsar Stents - Secondary Patency |
99.3; 98.2 | — |
| SECONDARY Functional Assessments for Subjects With the Astron and Pulsar Stents - Ankle - Brachial Index (ABI) Measurement |
0.71; 0.70; 0.94; 0.91; 0.23; 0.22 | — |
| SECONDARY Functional Assessments for Subjects With the Astron and Pulsar Stents - Six-Minute Walk Test |
868.9; 875.3; 1026.4; 1088.9; 157.5; 213.6 | — |
| SECONDARY Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire PAD Specific Score |
36.2; 36.7; 80.1; 75.8; 43.9; 39.1 | — |
| SECONDARY Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire Walking Distance Score |
21.3; 26.1; 62.0; 58.7; 40.7; 32.6 | — |
| SECONDARY Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire Walking Speed Score |
22.3; 25.2; 43.8; 43.5; 21.5; 18.3 | — |
| SECONDARY Functional Assessments for Subjects With the Astron and Pulsar Stents - Walking Impairment Questionnaire Stair Climbing Score |
30.0; 36.8; 56.1; 56.9; 26.1; 20.1 | — |
| SECONDARY Acute Procedural Success for Astron and Pulsar Stent |
95.0; 98.0 | — |
| SECONDARY Clinical Success |
95.0; 97.7 | — |
| SECONDARY Secondary Safety Assessment for Astron and Pulsar Stent: Adverse Event Rates |
67; 180; 94; 277 | — |
| SECONDARY Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - 30 Day MAE Rate |
0.0; 2.2; 0.0; 0.5 | — |
| SECONDARY Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Primary Patency at 12-months |
80.0; 90.7; 59.8; 69.9 | — |
| SECONDARY Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Primary Assisted Patency at 12-Months |
100.0; 97.8; 96.4; 100.0 | — |
| SECONDARY Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Secondary Patency Rate at 12-Months |
100.0; 99.3; 97.6; 98.4 | — |
| SECONDARY Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - Acute Procedure Success |
100.0; 94.6; 97.8; 98.1 | — |
| SECONDARY Comparison of Endpoints Results Between Occlusive and Non-occlusive Lesions for Astron and Pulsar Stent - 30-Day Clinical Success |
100.0; 94.6; 97.8; 97.6 | — |
| SECONDARY Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - MAE Rate |
10.9; 25.0 | — |
| SECONDARY Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Primary Patency at 12 Months |
68.5; 54.5 | — |
| SECONDARY Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Stent Fracture Rate at 12 Months |
4.7; 13.3 | — |
| SECONDARY Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Primary Assisted Patency at 12 Months |
99.2; 97.1 | — |
| SECONDARY Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Secondary Patency Rate at 12 Months |
98.8; 94.1 | — |
| SECONDARY Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - Acute Procedure Success |
98.1; 97.3 | — |
| SECONDARY Comparison of Endpoint Results Between Standard and Long Lesions for the Pulsar Stent - 30-day Clinical Success |
97.7; 97.2 | — |
| SECONDARY Number of Participants With Freedom From Clinically-driven TLR and Index Limb Amputation at 24 Months (Post Approval) |
217 | — |
| SECONDARY Safety Assessment for the Pulsar Stent: Percentage of Participants With Mortality, TLR, and Index Limb Amputation (Post Approval) |
19.3; 0.4; 19.0; 0.8 | — |
| SECONDARY Percentage of Participants for the Pulsar Stent Group With MAE (30-day Mortality, Clinically-driven TLR, and Index Limb Amputation) and Their Components at 36 Months (Post Approval). |
22.1; 0.4; 21.8; 1.2 | — |
| SECONDARY Percentage of Participants With Target Lesion Revascularization (TLR) at 24 Months (Post Approval) (Pulsar Stent Group) |
20.9 | — |
| SECONDARY Percentage of Participants With Target Lesion Revascularization (TLR) at 36 Months (Post Approval) (Pulsar Stent Group) |
23.7 | — |
| SECONDARY Number of Participants With Stent Fracture at 24 Months (Post Approval). |
10 | — |
| SECONDARY Number of Participants With Stent Fracture at 36 Months (Post Approval) (Pulsar Stent Group). |
13 | — |
| SECONDARY Percentage of Subjects With Serious Adverse Events at 36 Months (Post Approval) (Pulsar Stent Group). |
230 | — |
Eligibility Criteria
Inclusion Criteria
To support the objectives of this study, the following initial inclusion criteria must be met for a subject to be enrolled and considered for the index procedure:
- Age ≥ 18 years
- Willingness to comply with study follow-up requirements
- Candidate for PTA
- Life-style limiting claudication or rest pain with an ABI ≤ 0.9 (resting or exercise). Thigh brachial index (TBI) may be used / performed if ABI is inadequate.
- Written informed consent
For a subject to receive an investigational stent, the following procedure-related criteria must be met:
- One de novo, restenotic or occluded lesion representing a femoro-popliteal or iliac indication OR Two de novo, restenotic or occluded lesions representing one femoro-popliteal indication and one iliac indication on contralateral limbs - (i.e. one lesion per limb)
- Lesions may be one solid lesion or a series of multiple, smaller lesions to be treated as one lesion
- Subjects with bilateral, SFA/PPA disease (i.e. one SFA/PPA lesion per limb) are eligible for enrollment into the study. The target lesion will be selected at the investigator's discretion based on study eligibility criteria. The contralateral SFA/PPA intervention may be performed at the time of the index procedure (prior to treatment of study lesion); however, the use of an investigational treatment is prohibited. If the contralateral SFA/PPA intervention is not performed at the time of the index procedure, the intervention must be performed at least 30 days after the index procedure. The use of an investigational treatment for the contralateral intervention is prohibited.
- Subjects with bilateral, iliac disease (i.e. one iliac lesion per limb) are eligible for enrollment into the study. The target lesion will be selected at the investigator's discretion based on study eligibility criteria. The contralateral iliac intervention may be performed at the time of the index procedure; however, the use of an investigational treatment is prohibited. If the contralateral iliac intervention is not performed at the time of the index procedure, the intervention must be performed at least 30 days after the index procedure. The use of an investigational treatment for the subsequent contralateral intervention is also prohibited.
- Femoro-popliteal lesions must be located at least 1 cm distal to the profunda femoris artery and at least 3 cm above the knee joint (radiographic joint space)
- Iliac lesions must be located only in either the common or external iliac artery
- Lesions must be treatable with a maximum of two stents
- Angiographic evidence of ≥ 70% stenosis or occlusion (operator visual assessment)
- Lesion length ≤ 190 mm (if de novo or restenotic) or ≤ 100 mm (if occluded)
- Target vessel reference diameter: 2.5 to 6 mm (SFA/PPA) or 6 to 9 mm (iliac arteries) by visual estimate
- Angiographic evidence of patent SFA and PPA (iliac indication) and angiographic evidence of at least one distal vessel runoff to the foot (both femoro-popliteal and iliac indications). Patent is defined as 70%) or occlusion of an ipsilateral, inflow artery (e.g. aortoiliac, common femoral) must be successfully treated (use of investigational treatment prohibited) just prior to treatment of the target lesion. Successful treatment is defined as no complications and less than 30% residual stenosis following intervention.
Exclusion Criteria
To support the objectives of this study, the following initial exclusion criteria must not be present for a subject to be enrolled:
- Subjects pregnant or planning to become pregnant during the course of the study
- Life expectancy of less than one year
- Rutherford-Becker category 5 or 6. Subjects with ulcers caused by venous disease may be enrolled in the study.
- Previously stented lesion(s) in the target vessel
- Target lesion(s) received previous treatment within 30 days prior to enrollment
- Prior peripheral vascular bypass surgery involving the target limb(s)
- Thrombophlebitis or deep
Data sourced from ClinicalTrials.gov (NCT01319812). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.